rasH2 Publications

rasH2 Model Page

Filter publications by application: All ADMET Tox & Safety Assessment
Filter publications by model type: All

Author(s)

(Date)

Paper Title

Citation

Model Type

Applications

Full Text

Cohen SM, et al.
Mouse over for full list
Cohen SM, Robinson D, MacDonald J
(2001) Alternative models for carcinogenicity testing. Toxicol. Sci. 64(1):14-9
Toyosawa K, et al.
Mouse over for full list
Toyosawa K, Okimoto K, Kobayashi I, Kijima K, Kikawa E, Kohchi M, Koujitani T, Tanaka K, Matsuoka N
(2001) Di(2-ethylhexyl)phthalate induces hepatocellular adenoma in transgenic mice carrying a human prototype c-Ha-ras gene in a 26-week carcinogenicity study. Toxicol Pathol 29(4):458-66
Koujitani T, et al.
Mouse over for full list
Koujitani T, Yasuhara K, Tamura T, Onodera H, Takagi H, Takizawa T, Hirose M, Hayashi Y, Mitsumori K
(2001) Lack of modifying effects of eugenol on development of lung proliferative lesions induced by urethane in transgenic mice carrying the human prototype c-Ha-ras gene. J Toxicol Sci 26(3):129-39
Birumachi J, et al.
Mouse over for full list
Birumachi J, Suzuki AK, Itoh K, Hioki K, Maruyama C, Ohnishi Y
(2001) Diesel exhaust-induced airway hyperresponsiveness in c-Ha-ras transgenic mice. Toxicology 163(2-3):145-52
Torii M, et al.
Mouse over for full list
Torii M, Itoh F, Yabuuchi K, Ohno K, Kominami G, Hirano K, Tasaki T, Nara H
(2001) Twenty-six-week carcinogenicity study of sulfamethoxazole in CB6F1-Tg-rasH2 mice. J Toxicol Sci 26(2):61-73
Mori I, et al.
Mouse over for full list
Mori I, Yasuhara K, Hayashi SM, Nonoyama T, Nomura T, Yanai T, Masegi T, Mitsumori K
(2001) Aberrant expression of cyclin D1 in pulmonary proliferative lesions induced by high doses of urethane in transgenic mice carrying the human prototype c-H-ras gene. J. Vet. Med. Sci. 63(3):261-8
Kobayashi K, et al.
Mouse over for full list
Kobayashi K, Sano F, Mutai M, Sugimoto J
(2000) Glomerulonephritis with fibrillary deposition in a transgenic mouse carrying the human prototype c-Ha-ras gene (rasH2 mouse). Toxicol Pathol 28(2):359-62
Mori I, et al.
Mouse over for full list
Mori I, Yasuhara K, Hayashi SM, Nonoyama T, Nomura T, Mitsumori K
(2000) Carcinogen dose-dependent variation in the transgene mutation spectrum in urethane-induced lung tumors in transgenic mice carrying the human prototype c-Ha-ras gene. Cancer Lett. 153(1-2):199-209
Mitsumori K, et al.
Mouse over for full list
Mitsumori K, Yasuhara K, Mori I, Hayashi S, Shimo T, Onodera H, Nomura T, Hayashi Y
(1998) Pulmonary fibrosis caused by N-methyl-N-nitrosourethane inhibits lung tumorigenesis by urethane in transgenic mice carrying the human prototype c-Ha-ras gene. Cancer Lett. 129(2):181-90
Hayashi S, et al.
Mouse over for full list
Hayashi S, Mori I, Nonoyama T, Mitsumori K
(1998) Point mutations of the c-H-ras gene in spontaneous liver tumors of transgenic mice carrying the human c-H-ras gene. Toxicol Pathol 26(4):556-61
Yamamoto S, et al.
Mouse over for full list
Yamamoto S, Urano K, Koizumi H, Wakana S, Hioki K, Mitsumori K, Kurokawa Y, Hayashi Y, Nomura T
(1998) Validation of transgenic mice carrying the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing. Environ. Health Perspect. 106 Suppl 1:57-69
Tsunematsu S, et al.
Mouse over for full list
Tsunematsu S, Saito H, Sato R, Morizane T, Ishii H
(1997) Role of H-ras gene in chronic liver damage in mice. By using transgenic mice carrying a human C-H-ras proto-oncogene without mutations. Biochem. Mol. Biol. Int. 42(2):371-9
Tsunematsu S, et al.
Mouse over for full list
Tsunematsu S, Saito H, Tada S, Ebinuma H, Tsuchiya M, Kumagai N, Morizane T, Nomura T, Ishii H
(1997) Susceptibility of experimental autoimmune hepatitis in transgenic mice overexpressing the c-H-ras gene. J. Gastroenterol. Hepatol. 12(4):319-24
Tsunematsu S, et al.
Mouse over for full list
Tsunematsu S, Saito H, Kagawa T, Morizane T, Hata J, Nakamura T, Ishii H, Tsuchiya M, Nomura T, Katsuki M
(1994) Hepatic tumors induced by carbon tetrachloride in transgenic mice carrying a human c-H-ras proto-oncogene without mutations. Int. J. Cancer 59(4):554-9
Doi ST, et al.
Mouse over for full list
Doi ST, Kimura M, Katsuki M
(1994) Site-specific mutation of the human c-Ha-ras transgene induced by dimethylbenzanthracene causes tissue-specific tumors in mice. Jpn. J. Cancer Res. 85(8):801-7
Ando K, et al.
Mouse over for full list
Ando K, Saitoh A, Hino O, Takahashi R, Kimura M, Katsuki M
(1992) Chemically induced forestomach papillomas in transgenic mice carry mutant human c-Ha-ras transgenes. Cancer Res. 52(4):978-82
Muto S, et al.
Mouse over for full list
Muto S, Katsuki M, Horie S
(2006) Rapid induction of skin tumors in human but not mouse c-Ha-ras proto-oncogene transgenic mice by chemical carcinogenesis. Cancer Sci. 97(9):842-7
Urano K, et al.
Mouse over for full list
Urano K, Suzuki S, Machida K, Eguchi N, Sawa N, Kikuchi K, Hattori Y, Usui T
(2007) Examination of percutaneous application in a 26-week carcinogenicity test in CB6F1-TG rasH2 mice. J Toxicol Sci 32(4):367-75
Kawabe M, et al.
Mouse over for full list
Kawabe M, Urano K, Suguro M, Numano T, Taguchi F, Tsutsumi H, Furukawa F
(2013) Tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in an ultra-short-term skin carcinogenesis bioassay using rasH2 mice. Vet. Pathol. 50(5):903-8
Krishna G, et al.
Mouse over for full list
Krishna G, Ganiger S, Kannan K, Gopalakrishnan G, Goel S
(2015) Reversibility of dopamine receptor antagonist-induced hyperprolactinemia and associated histological changes in Tg RasH2 wild-type mice. Reprod. Toxicol. 58:73-8
Fielden MR, et al.
Mouse over for full list
Fielden MR, Dean C, Black K, Sawant SG, Subramanian R, Tomlinson JE, Walter S, Zimmermann C, Griggs MW, McKeon ME, Lewis EM, Beevers C, Pyrah I
(2016) Nonclinical Safety Profile of Etelcalcetide, a Novel Peptide Calcimimetic for the Treatment of Secondary Hyperparathyroidism. Int. J. Toxicol. 35(3):294-308
Sano T, et al.
Mouse over for full list
Sano T, Takai Y, Anayama H, Watanabe T, Fukuda R
(2016) Accumulation of Mott cells in the spleen in a CB6F1-Tg rasH2 mouse. J Toxicol Pathol 29(4):265-268
Suguro M, et al.
Mouse over for full list
Suguro M, Numano T, Kawabe M, Doi Y, Imai N, Mera Y, Tamano S
(2017) Lung Tumor Induction by 26-week Dermal Application of 1,2-Dichloroethane in CB6F1-Tg rasH2 Mice. Toxicol Pathol 45(3):427-434
Sano T, et al.
Mouse over for full list
Sano T, Watanabe T, Ishimura Y, Anayama H
(2017) Immunohistochemical characterization of urethane-induced lung tumors in CB6F1-Tg rasH2 mice. J Toxicol Pathol 30(2):177-181
Paranjpe MG, et al.
Mouse over for full list
Paranjpe MG, Belich J, Vidmar TJ, Elbekai RH, McKeon M, Brown C
(2017) Tg.rasH2 Mice and not CByB6F1 Mice Should Be Used for 28-Day Dose Range Finding Studies Prior to 26-Week Tg.rasH2 Carcinogenicity Studies. Int. J. Toxicol. 36(4):287-292
Kuroda H, et al.
Mouse over for full list
Kuroda H, Kinomoto T, Ogawa S, Kawabe M, Suguro M, Naraoka H, Takamatsu K, Oishi Y
(2018) Progression process and safety assessment adaptation of endometrial lesions in ENU-induced 2-stage uterine carcinogenicity in a Tg-rasH2 mouse model. J Toxicol Pathol 31(1):35-41
Boyle MH, et al.
Mouse over for full list
Boyle MH, Paranjpe MG, Creasy DM
(2018) High Background Incidence of Spontaneous Subcapsular Adrenal Gland Hyperplasia of Tg.rasH2 Mice Used in 26-week Carcinogenicity Studies. Toxicol Pathol 46(4):444-448
Teo S, et al.
Mouse over for full list
Teo S, Paranjpe M, Mckeon M, Mann P, Lee S, LaRock R, Brown T
(2018) The Antitussive Benzonatate Is Not Tumorigenic in Rodent Carcinogenicity Studies. Toxicol Pathol 46(6):683-692
Kim TW, et al.
Mouse over for full list
Kim TW, Papagiannis CN, Zwick LS, Engelhardt JA, Hoffmaster CM, Post NM, Matson JE, Hsiao JA, Burel SA, Henry SP
(2019) Comparison of the Class Effects of Antisense Oligonucleotides in CByB6F1-Tg(HRAS)2Jic and CD-1 Mice. Toxicol Pathol 47(1):82-92
Fujiwara K, et al.
Mouse over for full list
Fujiwara K, Yazama H, Donishi R, Koyama S, Fukuhara T, Takeuchi H
(2019) Inhibitory Effects of Glucosylceramide on Tumorigenesis Induced by a Carcinogen in Mice. Laryngoscope
Chen R, et al.
Mouse over for full list
Chen R, Zhou C, Cao Y, Xi J, Ohira T, He L, Huang P, You X, Liu W, Zhang X, Ma S, Xie T, Chang Y, Luan Y
(2020) Assessment of Pig-a, Micronucleus, and Comet Assay Endpoints in Tg.RasH2 Mice Carcinogenicity Study of Aristolochic Acid I. Environ. Mol. Mutagen. 61(2):266-275
Nishimura I, et al.
Mouse over for full list
Nishimura I, Doi Y, Imai N, Kawabe M, Mera Y, Shiina T
(2019) Carcinogenicity of intermediate frequency magnetic field in Tg.rasH2 mice. Bioelectromagnetics 40(3):160-169
Paranjpe MG, et al.
Mouse over for full list
Paranjpe MG, Belich JL, Mann PC, McKeon ME, Elbekai RH, Brown CM, Patrick DJ
(2019) A Comparison of Spontaneous Tumors in Tg.rasH2 Mice in 26-week Carcinogenicity Studies Conducted at a Single Test Facility during 2004 to 2012 and 2013 to 2018. Toxicol Pathol 47(1):18-25
Suarez-Torres JD, et al.
Mouse over for full list
Suarez-Torres JD, Jimenez-Orozco FA, Ciangherotti CE
(2020) Drug excipients, food additives, and cosmetic ingredients probably not carcinogenic to humans reveal a functional specificity for the 2-year rodent bioassay. J Appl Toxicol
Suarez-Torres JD, et al.
Mouse over for full list
Suarez-Torres JD, Jimenez-Orozco FA, Ciangherotti CE
(2020) The 2-year rodent bioassay in drug and chemical carcinogenesis testing: Sensitivity, according to the framework of carcinogenic action. Toxicol. Mech. Methods 30(6):462-475
Koujitani T, et al.
Mouse over for full list
Koujitani T, Yasuhara K, Usui T, Nomura T, Onodera H, Takagi H, Hirose M, Mitsumori K
(2000) Lack of susceptibility of transgenic mice carrying the human c-Ha-ras proto-oncogene (rasH2 mice) to phenolphthalein in a 6-month carcinogenicity study. Cancer Lett. 152(2):211-6
Urano K, et al.
Mouse over for full list
Urano K, Tamaoki N, Nomura T
(2012) Establishing a laboratory animal model from a transgenic animal: RasH2 mice as a model for carcinogenicity studies in regulatory science. Vet. Pathol. 49(1):16-23
Ozaki M, et al.
Mouse over for full list
Ozaki M, Ozaki K, Watanabe T, Uwagawa S, Okuno Y, Shirai T
(2005) Susceptibilities of p53 knockout and rasH2 transgenic mice to urethane-induced lung carcinogenesis are inherited from their original strains. Toxicol Pathol 33(2):267-71
Lee BS, et al.
Mouse over for full list
Lee BS, Park SJ, Kim YB, Han JS, Jeong EJ, Moon KS, Son HY
(2015) A 28-day oral gavage toxicity study of 3-monochloropropane-1,2-diol (3-MCPD) in CB6F1-non-Tg rasH2 mice. Food Chem. Toxicol. 86:95-103
Shah SA, et al.
Mouse over for full list
Shah SA, Paranjpe MG, Atkins PI, Zahalka EA
(2012) Reduction in the number of animals and the evaluation period for the positive control group in Tg.rasH2 short-term carcinogenicity studies. Int. J. Toxicol. 31(5):423-9
Umemura T, et al.
Mouse over for full list
Umemura T, Kodama Y, Hioki K, Nomura T, Nishikawa A, Hirose M, Kurokawa Y
(2002) The mouse rasH2/BHT model as an in vivo rapid assay for lung carcinogens. Jpn. J. Cancer Res. 93(8):861-6
Watanabe T, et al.
Mouse over for full list
Watanabe T, Kashida Y, Yasuhara K, Koujitani T, Hirose M, Mitsumori K
(2002) Rapid induction of uterine endometrial proliferative lesions in transgenic mice carrying a human prototype c-Ha-ras gene (rasH2 mice) given a single intraperitoneal injection of N-ethyl-N-nitrosourea. Cancer Lett. 188(1-2):39-46
Palazzi X, et al.
Mouse over for full list
Palazzi X, Kergozien-Framery S
(2009) Use of rasH2 transgenic mice for carcinogenesis testing of medical implants. Exp. Toxicol. Pathol. 61(5):433-41
Kawai M, et al.
Mouse over for full list
Kawai M, Jin M, Nishimura J, Dewa Y, Saegusa Y, Matsumoto S, Taniai E, Shibutani M, Mitsumori K
(2008) Hepatocarcinogenic susceptibility of fenofibrate and its possible mechanism of carcinogenicity in a two-stage hepatocarcinogenesis model of rasH2 mice. Toxicol Pathol 36(7):950-7
Okamura M, et al.
Mouse over for full list
Okamura M, Sumida K, Muto T, Kashida Y, Machida N, Watanabe T, Mitsumori K
(2004) Analysis of gene expression profiles of forestomach tumors in rasH2 mice initiated with N-ethyl-N-nitrosourea. Arch. Toxicol. 78(12):688-96
Storer RD, et al.
Mouse over for full list
Storer RD, French JE, Donehower LA, Gulezian D, Mitsumori K, Recio L, Schiestl RH, Sistare FD, Tamaoki N, Usui T, van Steeg H,
(2003) Transgenic tumor models for carcinogen identification: the heterozygous Trp53-deficient and RasH2 mouse lines. Mutat. Res. 540(2):165-76
Katsutani N, et al.
Mouse over for full list
Katsutani N, Sekido T, Aoki T, Sagami F
(2000) Hepatic drug metabolizing enzymes induced by clofibrate in rasH2 mice. Toxicol. Lett. 115(3):223-9
Sobajima A, et al.
Mouse over for full list
Sobajima A, Haniu H, Nomura H, Tanaka M, Takizawa T, Kamanaka T, Aoki K, Okamoto M, Yoshida K, Sasaki J, Ajima K, Kuroda C, Ishida H, Okano S, Ueda K, Kato H, Saito N
(2019) Organ accumulation and carcinogenicity of highly dispersed multi-walled carbon nanotubes administered intravenously in transgenic rasH2 mice. Int J Nanomedicine 14:6465-6480
Okamura M, et al.
Mouse over for full list
Okamura M, Moto M, Kashida Y, Machida N, Mitsumori K
(2004) Carcinogenic susceptibility to N-bis(2-hydroxypropyl)nitrosamine (DHPN) in rasH2 mice. Toxicol Pathol 32(4):474-81
Cho WS, et al.
Mouse over for full list
Cho WS, Jeong J, Choi M, Park SN, Han BS, Son WC
(2011) 26-Week carcinogenicity study of di-isodecyl phthalate by dietary administration to CB6F1-rasH2 transgenic mice. Arch. Toxicol. 85(1):59-66
Machida K, et al.
Mouse over for full list
Machida K, Urano K, Yoshimura M, Tsutsumi H, Nomura T, Usui T
(2008) Carcinogenic comparative study on rasH2 mice produced by two breeding facilities. J Toxicol Sci 33(4):493-501
Okamura M, et al.
Mouse over for full list
Okamura M, Unami A, Moto M, Muguruma M, Ito T, Jin M, Oishi Y, Kashida Y, Mitsumori K
(2007) The possible mechanism of enhanced carcinogenesis induced by genotoxic carcinogens in rasH2 mice. Cancer Lett. 245(1-2):321-30
Umemura T, et al.
Mouse over for full list
Umemura T, Kodama Y, Hioki K, Inoue T, Nomura T, Kurokawa Y
(1999) Susceptibility to urethane carcinogenesis of transgenic mice carrying a human prototype c-Ha-ras gene (rasH2 mice) and its modification by butylhydroxytoluene. Cancer Lett. 145(1-2):101-6
Jin M, et al.
Mouse over for full list
Jin M, Takahashi M, Moto M, Muguruma M, Ito K, Watanabe K, Kenmochi Y, Kono T, Hasumi K, Mitsumori K
(2007) Carcinogenic susceptibility of rasH2 mice to troglitazone. Arch. Toxicol. 81(12):883-94
Park HJ, et al.
Mouse over for full list
Park HJ, Oh JH, Park SM, Cho JW, Yum YN, Park SN, Yoon DY, Yoon S
(2011) Identification of biomarkers of chemically induced hepatocarcinogenesis in rasH2 mice by toxicogenomic analysis. Arch. Toxicol. 85(12):1627-40
Umemura T, et al.
Mouse over for full list
Umemura T, Kodama Y, Nishikawa A, Hioki K, Nomura T, Kanki K, Kuroiwa Y, Ishii Y, Kurokawa Y, Hirose M
(2006) Nine-week detection of six genotoxic lung carcinogens using the rasH2/BHT mouse model. Cancer Lett. 231(2):314-8
Narushima S, et al.
Mouse over for full list
Narushima S, Sakata T, Hioki K, Itoh T, Nomura T, Itoh K
(2010) Inhibitory effect of yogurt on aberrant crypt foci formation in the rat colon and colorectal tumorigenesis in RasH2 mice. Exp. Anim. 59(4):487-94
Nesfield SR, et al.
Mouse over for full list
Nesfield SR, Clarke CJ, Hoivik DJ, Miller RT, Allen JS, Selinger K, Santostefano MJ
(2005) Evaluation of the carcinogenic potential of clofibrate in the rasH2 mouse. Int. J. Toxicol. 24(5):301-11
Nambiar PR, et al.
Mouse over for full list
Nambiar PR, Turnquist SE, Morton D
(2012) Spontaneous tumor incidence in rasH2 mice: review of internal data and published literature. Toxicol Pathol 40(4):614-23
Tsuji S, et al.
Mouse over for full list
Tsuji S, Kuwahara Y, Takagi H, Sugiura M, Nakanishi Y, Wakamatsu M, Tsuritani K, Sato Y
(2015) Gene expression analysis in the lung of the rasH2 transgenic mouse at week 4 prior to induction of malignant tumor formation by urethane and N-methylolacrylamide. J Toxicol Sci 40(6):685-700
Tomisawa M, et al.
Mouse over for full list
Tomisawa M, Suemizu H, Ohnishi Y, Maruyama C, Urano K, Usui T, Yasuhara K, Tamaoki N, Mitsumori K
(2003) Mutation analysis of vinyl carbamate or urethane induced lung tumors in rasH2 transgenic mice. Toxicol. Lett. 142(1-2):111-7
Takanashi S, et al.
Mouse over for full list
Takanashi S, Hara K, Aoki K, Usui Y, Shimizu M, Haniu H, Ogihara N, Ishigaki N, Nakamura K, Okamoto M, Kobayashi S, Kato H, Sano K, Nishimura N, Tsutsumi H, Machida K, Saito N
(2012) Carcinogenicity evaluation for the application of carbon nanotubes as biomaterials in rasH2 mice. Sci Rep 2:498
Curtin GM, et al.
Mouse over for full list
Curtin GM, Higuchi MA, Ayres PH, Swauger JE, Mosberg AT
(2004) Lung tumorigenicity in A/J and rasH2 transgenic mice following mainstream tobacco smoke inhalation. Toxicol. Sci. 81(1):26-34
Umemura T, et al.
Mouse over for full list
Umemura T, Kodama Y, Hioki K, Inoue T, Nomura T, Kurokawa Y
(2001) Butylhydroxytoluene (BHT) increases susceptibility of transgenic rasH2 mice to lung carcinogenesis. J. Cancer Res. Clin. Oncol. 127(10):583-90
Imai T, et al.
Mouse over for full list
Imai T, Yasuhara K, Tamura T, Takizawa T, Ueda M, Hirose M, Mitsumori K
(2002) Inhibitory effects of cinnamaldehyde on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung carcinogenesis in rasH2 mice. Cancer Lett. 175(1):9-16
Takaoka M, et al.
Mouse over for full list
Takaoka M, Sehata S, Maejima T, Imai T, Torii M, Satoh H, Toyosawa K, Tanakamaru ZY, Adachi T, Hisada S, Ueda M, Ogasawara H, Matsumoto M, Kobayashi K, Mutai M, Usui T
(2003) Interlaboratory comparison of short-term carcinogenicity studies using CB6F1-rasH2 transgenic mice. Toxicol Pathol 31(2):191-9
Tamaoki N
Mouse over for full list
Tamaoki N
(2001) The rasH2 transgenic mouse: nature of the model and mechanistic studies on tumorigenesis. Toxicol Pathol 29 Suppl:81-9
Nambiar PR, et al.
Mouse over for full list
Nambiar PR, Morton D
(2013) The rasH2 mouse model for assessing carcinogenic potential of pharmaceuticals. Toxicol Pathol 41(8):1058-67
Bogdanffy MS, et al.
Mouse over for full list
Bogdanffy MS, Lesniak J, Mangipudy R, Sistare FD, Colman K, Garcia-Tapia D, Monticello T, Blanset D
(2020) Tg.rasH2 Mouse Model for Assessing Carcinogenic Potential of Pharmaceuticals: Industry Survey of Current Practices. Int. J. Toxicol. :1091581820919896
ADMET
Kawabe M, et al.
Mouse over for full list
Kawabe M, Urano K, Suguro M, Hara T, Kageyama Y, Mera Y, Tsutsumi H
(2019) Establishment and Validation of an Ultra-Short-Term Skin Carcinogenicity Bioassay Using Tg-rasH2 Mice. Vet. Pathol. :300985819854440
Saitoh A, et al.
Mouse over for full list
Saitoh A, Kimura M, Takahashi R, Yokoyama M, Nomura T, Izawa M, Sekiya T, Nishimura S, Katsuki M
(1990) Most tumors in transgenic mice with human c-Ha-ras gene contained somatically activated transgenes. Oncogene 5(8):1195-200
Paranjpe MG, et al.
Mouse over for full list
Paranjpe MG, Elbekaei RH, Shah SA, Hickman M, Wenk ML, Zahalka EA
(2013) Historical control data of spontaneous tumors in transgenic CByB6F1-Tg(HRAS)2Jic (Tg.rasH2) mice. Int. J. Toxicol. 32(1):48-57
Paranjpe MG, et al.
Mouse over for full list
Paranjpe MG, Shah SA, Denton MD, Elbekai RH
(2013) Incidence of spontaneous non-neoplastic lesions in transgenic CBYB6F1-Tg(HRAS)2Jic mice. Toxicol Pathol 41(8):1137-45
Paranjpe MG, et al.
Mouse over for full list
Paranjpe MG, Denton MD, Elbekai RH
(2014) The 26-week Tg.rasH2 mice carcinogenicity studies: microscopic examination of only select tissues in low- and mid-dose groups. Toxicol Pathol 42(7):1153-7
Paranjpe MG, et al.
Mouse over for full list
Paranjpe MG, Denton MD, Vidmar TJ, Elbekai RH
(2014) Relationship of body weight parameters with the incidence of common spontaneous tumors in Tg.rasH2 mice. Toxicol Pathol 42(7):1143-52
Paranjpe MG, et al.
Mouse over for full list
Paranjpe MG, Denton MD, Vidmar T, Elbekai RH
(2014) Trend analysis of body weight parameters, mortality, and incidence of spontaneous tumors in Tg.rasH2 mice. Int. J. Toxicol. 33(6):475-81
Paranjpe MG, et al.
Mouse over for full list
Paranjpe MG, Denton MD, Vidmar TJ, Elbekai RH
(2015) Regulatory Forum Opinion Piece*: Retrospective Evaluation of Doses in the 26-week Tg.rasH2 Mice Carcinogenicity Studies: Recommendation to Eliminate High Doses at Maximum Tolerated Dose (MTD) in Future Studies. Toxicol Pathol 43(5):611-20
Paranjpe MG, et al.
Mouse over for full list
Paranjpe MG, Denton MD, Vidmar TJ, Elbekai RH
(2016) Regulatory Forum Opinion Piece*: Retrospective Evaluation of Doses in the 26-week Tg.rasH2 Mice Carcinogenicity Studies: Recommendation to Eliminate High Doses at Maximum Tolerated Dose in Future Studies. A Response to the Counterpoints. Toxicol Pathol 44(1):5-8
Paranjpe MG, et al.
Mouse over for full list
Paranjpe MG, Belich JL, McKeon ME, Elbekai RH, Mann PC, Hard GC, Seely JC
(2016) Renal Tumors in 26-Week Tg.Rash2 Mice Carcinogenicity Studies. Toxicol Pathol 44(5):633-5
Paranjpe MG, et al.
Mouse over for full list
Paranjpe MG, Belich JL, Richardson DR, Vidmar T, Mann PC, McKeon ME, Elbekai RH
(2016) Progression of Serosal Vascular Proliferative Lesions to Hemangiosarcomas in the Uterus of the 26-Week Tg.rasH2 Mice Carcinogenicity Studies. Int. J. Toxicol.
ADMET, Tox & Safety Assessment
Pritchard JB, et al.
Mouse over for full list
Pritchard JB, French JE, Davis BJ, Haseman JK
(2003) The role of transgenic mouse models in carcinogen identification. Environ. Health Perspect. 111(4):444-54
Yamamoto S, et al.
Mouse over for full list
Yamamoto S, Urano K, Nomura T
(1998) Validation of transgenic mice harboring the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing. Toxicol. Lett. 102-103:473-8
Yamamoto S, et al.
Mouse over for full list
Yamamoto S, Mitsumori K, Kodama Y, Matsunuma N, Manabe S, Okamiya H, Suzuki H, Fukuda T, Sakamaki Y, Sunaga M, Nomura G, Hioki K, Wakana S, Nomura T, Hayashi Y
(1996) Rapid induction of more malignant tumors by various genotoxic carcinogens in transgenic mice harboring a human prototype c-Ha-ras gene than in control non-transgenic mice. Carcinogenesis 17(11):2455-61
Usui T, et al.
Mouse over for full list
Usui T, Mutai M, Hisada S, Takoaka M, Soper KA, McCullough B, Alden C
(2001) CB6F1-rasH2 mouse: overview of available data. Toxicol Pathol 29 Suppl:90-108
Urano K, et al.
Mouse over for full list
Urano K, Suzuki S, Machida K, Sawa N, Eguchi N, Kikuchi K, Fukasawa K, Taguchi F, Usui T
(2006) Use of IC tags in short-term carcinogenicity study on CB6F1 TGrasH2 mice. J Toxicol Sci 31(5):407-18
Takegawa K, et al.
Mouse over for full list
Takegawa K, Mitsumori K, Yasuhara K, Moriyasu M, Sakamori M, Onodera H, Hirose M, Nomura T
(2000) A mechanistic study of ovarian carcinogenesis induced by nitrofurazone using rasH2 mice. Toxicol Pathol 28(5):649-55
Suemizu H, et al.
Mouse over for full list
Suemizu H, Muguruma K, Maruyama C, Tomisawa M, Kimura M, Hioki K, Shimozawa N, Ohnishi Y, Tamaoki N, Nomura T
(2002) Transgene stability and features of rasH2 mice as an animal model for short-term carcinogenicity testing. Mol. Carcinog. 34(1):1-9
Ohnishi Y, et al.
Mouse over for full list
Ohnishi Y, Arai T, Koshirakawa M, Horii N, Nakajo S, Urano K, Usui T, Tamaoki N, Ueyama Y
(2001) Induction of drug metabolism-related enzymes by methylcholanthrene and phenobarbital in transgenic mice carrying human prototype c-Ha-ras gene and their wild type littermates. Exp. Anim. 50(1):33-9
Morton D, et al.
Mouse over for full list
Morton D, Alden CL, Roth AJ, Usui T
(2002) The Tg rasH2 mouse in cancer hazard identification. Toxicol Pathol 30(1):139-46
Mitsumori K, et al.
Mouse over for full list
Mitsumori K, Koizumi H, Nomura T, Yamamoto S
(1998) Pathological features of spontaneous and induced tumors in transgenic mice carrying a human prototype c-Ha-ras gene used for six-month carcinogenicity studies. Toxicol Pathol 26(4):520-31
Maronpot RR, et al.
Mouse over for full list
Maronpot RR, Mitsumori K, Mann P, Takaoka M, Yamamoto S, Usui T, Okamiya H, Nishikawa S, Nomura T
(2000) Interlaboratory comparison of the CB6F1-Tg rasH2 rapid carcinogenicity testing model. Toxicology 146(2-3):149-59
Kanno H, et al.
Mouse over for full list
Kanno H, Tanakamaru ZY, Ishimura Y, Kandori H, Yamasaki H, Sasaki S
(2003) Historical Background Data in CB6F1-Tg-rasH2 Mice and CB6F1-nonTg-rasH2 Mice over a 26-Week Experimental Period J Toxicol Pathol. 16(4):267-274
Gulezian D, et al.
Mouse over for full list
Gulezian D, Jacobson-Kram D, McCullough CB, Olson H, Recio L, Robinson D, Storer R, Tennant R, Ward JM, Neumann DA
(2000) Use of transgenic animals for carcinogenicity testing: considerations and implications for risk assessment. Toxicol Pathol 28(3):482-99
Close

Welcome! Tell us a little about yourself